Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 4, 2006, Pages 396-402

  Kaneshiro, Yasunori ^a   Oda, Yutaka ^a   Iwakiri, Kentaro ^a   Masada, Toshiaki ^a   Iwaki, Hiroyoshi ^a   Hirota, Yoshio ^a   Kondo, Kyoko ^a   Takaoka, Kunio ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOCHROME P450 3A; MIDAZOLAM; PREDNISOLONE;

ADULT; ALCOHOL CONSUMPTION; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BELL PALSY; BONE NECROSIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID INDUCED OSTEONECROSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG CLEARANCE; EATON LAMBERT SYNDROME; ENZYME ACTIVITY; FEMALE; FEMUR HEAD; HIP FRACTURE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MULTIVARIATE ANALYSIS; NEPHRITIS; ORTHOPEDIC SURGERY; OSTEOPOROSIS; PREGNANCY TOXEMIA; PRIORITY JOURNAL; RHEUMATIC DISEASE; RISK; SKIN DISEASE; STATISTICAL SIGNIFICANCE;

ADRENAL CORTEX HORMONES; ADULT; CYTOCHROME P-450 CYP3A; FEMALE; FEMUR HEAD; HUMANS; LIVER; MALE; MIDAZOLAM; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORTHOPEDIC PROCEDURES; OSTEONECROSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 33749248514     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.07.004     Document Type: Article

References (28)

1. Mankin H.J. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 326 (1992) 1473-1479
2. Mont M.A., and Hungerford D.S. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 77 (1995) 459 -4
3. Hirota Y., Hotokebuchi T., and Sugioka Y. Idiopathic osteonecrosis of the femoral head; nationwide epidemiologic studies in Japan. In: Urbaniak J.R., and Jones Jr. J.P. (Eds). Osteonecrosis: etiology, diagnosis, and treatment (1997), American Academy of Orthopaedic Surgeons, Rosemont (IL) 51-58
4. Hirota Y., Hirohata T., Fukuda K., Mori M., Yanagawa H., Ohno Y., et al. Association of alcohol intake, cigarette smoking, and occupational status with the risk of idiopathic osteonecrosis of the femoral head. Am J Epidemiol 137 (1993) 530-538
5. Zizic T.M., Marcoux C., Hungerford D.S., Dansereau J.V., and Stevens M.B. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 79 (1985) 596-604
6. Kalla A.A., Learmonth I.D., and Klemp P. Early treatment of avascular necrosis in systemic lupus erythematosus. Ann Rheum Dis 45 (1986) 649-652
7. Mont M.A., Glueck C.J., Pacheco I.H., Wang P., Hungerford D.S., and Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24 (1997) 654-662
8. Ono K., Tohjima T., and Komazawa T. Risk factors of avascular necrosis of the femoral head in patients with systemic lupus erythematosus under high-dose corticosteroid therapy. Clin Orthop (1992) 89-97
9. Oinuma K., Harada Y., Nawata Y., Takabayashi K., Abe I., Kamikawa K., et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 60 (2001) 1145-1148
10. Nagasawa K., Tada Y., Koarada S., Horiuchi T., Tsukamoto H., Murai K., et al. Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 14 (2005) 385-390
11. Massardo L., Jacobelli S., Leissner M., Gonzalez M., Villarroel L., and Rivero S. High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus 1 (1992) 401-405
12. Nagasawa K., Ishii Y., Mayumi T., Tada Y., Ueda A., Yamauchi Y., et al. Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 48 (1989) 672-676
13. Varis T., Kivisto K.T., Backman J.T., and Neuvonen P.J. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 68 (2000) 487-494
14. Varis T., Kaukonen K.M., Kivisto K.T., and Neuvonen P.J. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 64 (1998) 363-368
15. Varis T., Kivisto K.T., and Neuvonen P.J. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 56 (2000) 57-60
16. Schellens J.H., Soons P.A., and Breimer D.D. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 37 (1988) 2507-2510
17. Lin Y.S., Lockwood G.F., Graham M.A., Brian W.R., Loi C.M., Dobrinska M.R., et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11 (2001) 781-791
18. Thummel K.E., Shen D.D., Podoll T.D., Kunze K.L., Trager W.F., Hartwell P.S., et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271 (1994) 549-556
19. Streetman D.S., Bertino Jr. J.S., and Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10 (2000) 187-216
20. Sugano N., Kubo T., Takaoka K., Ohzono K., Hotokebuchi T., Matsumoto T., et al. Diagnostic criteria for non-traumatic osteonecrosis of the femoral head. A multicentre study. J Bone Joint Surg Br 81 (1999) 590-595
21. Sugano N., Atsumi T., Ohzono K., Kubo T., Hotokebuchi T., and Takaoka K. The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head. J Orthop Sci 7 (2002) 601-605
22. Jones Jr. J.P. Risk factors potentially activating intravascular coagulation and causing nontraumatic osteonecrosis. In: Urbaniak J.R., and Jones Jr. J.P. (Eds). Osteonecrosis: etiology, diagnosis, and treatment (1997), American Academy of Orthopaedic Surgeons, Rosemont (IL) 89-133
23. Rendic S., and Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29 (1997) 413-580
24. Hase I., Oda Y., Tanaka K., Mizutani K., Nakamoto T., and Asada A. I.v. fentanyl decreases the clearance of midazolam. Br J Anaesth 79 (1997) 740-753
25. Hamaoka N., Oda Y., Hase I., Mizutani K., Nakamoto T., Ishizaki T., et al. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. Clin Pharmacol Ther 66 (1999) 110-117
26. Eap C.B., Buclin T., Cucchia G., Zullino D., Hustert E., Bleiber G., et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 60 (2004) 237-246
27. Kinirons M.T., O'Shea D., Kim R.B., Groopman J.D., Thummel K.E., Wood A.J., et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 66 (1999) 224-231
28. Lamba J.K., Lin Y.S., Schuetz E.G., and Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54 (2002) 1271-1294